A B S T R AC T
Background. High levels of preformed anti-HLA antibodies dramatically diminish renal transplant outcomes. Most desensitization programmes guarantee good intermediate outcomes but quite disappointing long-term prognosis. The search for a fully compatible kidney increases time on the waiting list. Methods. In February 2011, a nationwide hyperimmune programme (NHP) was begun in Italy: all available kidneys are primarily proposed to highly sensitized patients with a panel reactive antibody above 80%. In this manuscript, we evaluate the outcome of paediatric patients transplanted with this approach. Results. Twenty-one patients were transplanted. Complete data are available for 20 patients. Mean age at transplantation was 14.5 years [standard deviation (SD) ± 5.5)]. Mean time on the waiting list was 29.3 months (SD ± 27.5). Median follow-up was 29.2 months (range: 11.2-59.3). The average number of HLA mismatches in these patients was 2.3 versus 3.7 in 48 standard patients transplanted in the same period (P < 0.001). Only one graft was lost. Two cases of humoral rejection occurred and were successfully treated. No cellular rejection was reported. Median creatinine clearance was 84, 88, 77 and 77 mL/min/ 1.73 m 2 respectively 1, 6, 12 and 24 months after transplant.
Conclusions.
Transplantation of sensitized patients avoiding prohibited antigens is feasible, at least in a selected cohort of patients. In order to be able to further improve this approach, which in our opinion is very successful, it would be necessary to expand the donor pool, possibly increasing the number of countries participating in the programme. In this series, time on the waiting list did not increase significantly. This allocation policy should ideally lead to an outcome comparable to that expected in standard patients, which is particularly desirable in young patients who have the longest life expectancy. Since long-term results of desensitization programmes are not (yet) convincing, we suggest that these programmes should be reserved for selected cases where compatible organs cannot be found within a reasonable time span.
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I N T R O D U C T I O N
High levels of preformed anti-HLA antibodies dramatically diminish renal transplant outcomes. According to the Organ Procurement and Transplantation Network, the number of highly sensitized patients on the transplant waiting list continues to increase [1] .
The highly sensitized patient is destined to remain on the waiting list for extended periods and, thus, on dialysis [1] .
For this reason, several desensitization programmes have been proposed, most of which have a very good short to intermediate outcome. Unfortunately, rejection rate in the first year is very high at 20-50% [2] and, even though it is usually possible to reverse the rejection, long-term outcome is still quite disappointing as graft loss due to antibody-mediated tissue injury may occur earlier than in standard patients with no immunologic memory versus donor antigens [3] .
Obviously, the best approach would be to transplant patients using kidneys from donors who have no antigens against which the recipient has already developed antibodies, not even at a low titre. Unfortunately, waiting for a suitable organ to become available would considerably increase the time spent on the transplant waiting list.
In Italy, the standard paediatric programme includes patients who reach a glomerular filtration rate below 15 mL/min/1.73 m 2 or who start renal replacement treatment when they are younger than 18 years old. Once on the waiting list, they may be transplanted even if they exceed the age of 18 years. These patients are offered organs only if the donor is under the age of 15 years. With such a definition, every year about 50 paediatric donors are available. This allows an acceptable median waiting time for 'standard' children (around 18 months) and does not lead to an increase in the number of patients on the waiting list, which is quite stable at between 100 and 130.
Unfortunately, this relatively small number of donors is insufficient to meet the needs of all the sensitized recipients who may remain on the waiting list for years without ever being selected for transplantation.
In February 2011, a nationwide hyperimmune programme (NHP) was therefore started: every kidney available in Italy is primarily proposed to patients who have, or have had at some moment of their clinical history, a panel reactive antibody (PRA) titre above 80%. This programme is offered to all patients, both adults and children. However, there is one difference: sensitized children may enter the programme as soon as they need a renal transplant, while adults must have spent at least 8 years on the standard waiting list before being enrolled in this special programme. The value of 80% cut-off is obviously arbitrary and was defined according to the total number of patients in that condition when the programme was set up.
All patients who enter the NHP must undergo a very careful characterization of their alloantibodies. Each available donor is first evaluated for allocation in the NHP context. Following a negative virtual cross-match, the organ is proposed to one of the patients. A current and historical cross-match is required before the final allocation and, if negative, the transplantation is performed. In this manuscript, we evaluate the outcome of paediatric patients transplanted with this approach.
M AT E R I A L S A N D M E T H O D S
All patients enrolled on the paediatric waiting list and transplanted since the NHP began were considered. Patients were treated in four different transplant centres.
Twenty-one patients were transplanted according to this programme; 15 received organs from the adult list and 6 received paediatric organs. We have some data on the follow-up of all of them but detailed information is available for 20 patients (Table 1) . Reported data refer to these 20 patients, 19 of whom had already received one previous transplant. Mean age at transplantation was 14.5 years [standard deviation (SD) ± 5.5)]. Mean time on the waiting list was 29.3 months (SD ± 27.5). Median follow-up was 29.2 months (range: 11.2-59.3). Median maximum PRA was 92.5% (range: 80-100). Median PRA at transplantation was 50% (range: 0-100) ( Table 1) . Primary renal diseases are reported in Table 2 .
Each transplant centre was allowed to provide immunosuppression according to local practice. However, centres used a rather homogenous protocol which included induction treatment with anti-lymphocytic serum in 14 patients (rabbit anti-thymocyte globulin) and basiliximab in 6, and a maintenance protocol with tacrolimus in 19 and cyclosporine in 1, as well as mycophenolate and steroids. Tacrolimus was maintained at trough levels between 8 and 12 ng/mL in the first month and between 4 and 8 ng/mL thereafter. Mycophenolate was provided to all patients: 300 mg/m 2 /dose twice a day. Prednisone was given to all patients in the dosage of 60 mg/m 2 and quickly tapered in the following months and maintained to a very low dose every other day.
Cross-match was performed according to local practice: cytotoxicity cross-match was performed in all patients and in five patients a flow cytometry cross-match was also implemented.
All patients/guardians had to sign an additional consent to be enrolled into this specific list. All data were recorded in a database. All patients or their legal representatives gave their informed consent for data storage in an electronic archive and it was considered unnecessary to ask for additional consent. Authorization to publish these data was obtained by the ethical committee.
Detection and characterization of hla antibodies Anti-HLA class I and class II IgG antibodies were tested with a bead-based detection assay. We used the LABScreen Mixed kit (One Lambda Inc., Canoga Park, CA, USA), which simultaneously detects class I and class II antibodies, and the single antigen bead (SAB) assays (Single Antigen kit, One Lambda) to identify HLAclass I and class II specificities. Before testing, all sera were pre-treated by disodium EDTA (final concentration 10 mM, pH 7.4) (Sigma-Aldrich, Milan, Italy) in order to rule out the underestimation of antibody mean fluorescence intensity (MFI) strength due to the prozone phenomenon. Screening assay results above a cut-off value of a ratio of 3.0 between sample and negative control were considered positive. Single antigen results above an MFI cut-off value of 1000 were considered positive. In only one patient, serum was tested with C1qScreen TM (One Lambda) for identification of complement binding antibodies.
R E S U LT S
Three patients were immediately enrolled at the start of the programme and 24 were enrolled in the following years up to 31 December 2015. Twenty-one patients were actually transplanted within this programme.
One graft was lost after transplantation due to humoral rejection. Primary non-function occurred. Renal biopsy confirmed a C4d-positive rejection. Cytotoxicity cross-match was performed on current and historical serum and found negative. Anti-HLA DSA antibodies were negative on pre-transplant sera and 1 and 10 days after transplant. On Day 15 a new search demonstrated a newly developed donor-specific antibody against A68, which was C1Q negative. The patient received steroid pulses, plasmapheresis and rituximab, but no treatment was effective and renal function never recovered.
Two more patients experienced clinical humoral rejections 10 and 30 days after transplant. Rejections were successfully treated with steroids, plasmapheresis and eculizumab. In both cases, post-transplant anti-HLA antibodies were detected, against DQ5 and DQ6 respectively. These antibodies were donor specific. In both cases these antibodies had not been detected before transplantation, but a new search, on pretransplant sera that had not been investigated before, showed that the antibodies were already present but were undetectable on the last pre-transplant serum. In both cases cytotoxicity cross-match had been performed on current and historical serum and found negative.
A fourth subclinical humoral rejection occurred 36 months after transplant. In this last case, de novo anti-HLA antibodies were detected. No cellular rejection occurred.
With the exception of the patient who lost his graft, renal function was fairly stable in all patients. Median creatinine clearance was 84, 88, 77 and 77 mL/min/1.73 m 2 respectively 1, 6, 12 and 24 months after transplant.
The average number of HLA mismatches was 2.3 (1.9 for class 1 and 0.4 for class 2), SD ± 1.3 (1.2 for class 1 and 0.5 for class 2) (range: 0-5). The average number of mismatches in 48 standard patients transplanted in the same period was 3.7 (2.6 for class 1 and 1.2 for class 2), SD ± 1.2 (0.9 for class 1 and 0.5 for class 2) (range: 2-6). The difference between the average numbers of mismatches in sensitized and standard patients was highly significant (P < 0.001) (Figure 1 ).
D I S C U S S I O N
The long-term deleterious effect of pre-transplant cytotoxic antibodies on graft survival is well known. Donor-specific antibodies may also develop 'de novo' during the follow-up of renal transplantation and in all cases they are associated with a shorter graft survival [4] .
Highly sensitized patients do not easily find a suitable organ and thus remain on the waiting list for a long time [1] . This condition carries several negative effects: long-term dialysis is associated with a high morbidity and mortality rate, has a profound impact on the patients and on their family's life, and may increase the risk of severe depression [5] [6] [7] [8] .
For this reason many transplant centres propose desensitization programmes [9] [10] [11] [12] . Most of these protocols allow a good short and intermediate outcome, but unfortunately long-term outcomes are still quite unsatisfactory [2, 3, 13] . This is particularly undesirable in children, as their life expectation is hopefully long. After a mean period of 30 months on the waiting list, the average age at transplantation in this cohort was 14.3 years. If a desensitization programme is applied, we could expect the kidney to last some 5-10 years after transplantation [3] . This would imply a return to dialysis at an age when patients would still be young and in a very significant period of their social and working life. At that time, they would need a new kidney. However, new antibodies that developed because of the failed graft would be added to the antibodies that made the desensitization protocol necessary at the first transplant. It would therefore be improbable that a new kidney could be found.
Searching for a favourable HLA match with no prohibited antigens is obviously not a new idea.
Within Eurotransplant, the Acceptable Mismatch Program was created in 1985 in order to find cross-match-negative donors for sensitized patients [14] . In this programme, very well matched donors were proposed for cross-matching. Also, programmes were set up in the UK (the so-called 'Save Our Souls' scheme) and the USA (Regional Organ Procurement, ROPinitiated by the Southeastern Organ Procurement organization) to provide an adequate kidney offer without any desensitizing protocol [14] . All these programmes achieved acceptable results but follow a 'trial-and-error' approach. The Eurotransplant programme has improved over the years [15, 16] , but does not guarantee a negative cross-match.
The Italian approach also does not require a desensitization policy but, in addition, does not even ask for a perfectly matched kidney as is the case in the Eurotransplant programme. Even though a minimum compatibility is recommended (1 HLA-DR and 1 HLA-A or HLA-B or HLA-DR identity), it is not mandatory. In fact, in our cohort, due to clinical reasons (difficult vascular access for dialysis), there were patients with up to five mismatches. This is now possible because Luminex technology allows a reliable characterization of most anti-HLA antibodies and the results of the cross-match may be anticipated in almost all cases based on patients' antibody screening and identification. In our experience, actual cross-match was always negative as predicted by virtual cross-match.
Three cases of rejection occurred, in one case leading to graft loss. Rejection rate was therefore almost as expected in a standard population of transplanted population.
Two of these rejections were the result of pre-existing cytotoxic antibodies, not previously detected. Antibodies were present in available but non-tested sera, and apparently disappeared in the follow-up period and were not detected during investigation of current sera. This is similar to what occurs in the desensitizing protocols where the titre of circulating cytotoxic antibodies is reduced by means of several procedures. However, immunologic memory remains and a high humoral rejection rate is in any case expected [2] .
In these two cases, cytotoxicity cross-match was performed on current and historical serum and found negative, but no flow-cytometric cross-match was performed. We wonder whether a flow cytometry cross-match could have predicted rejections more effectively. In any case, this reinforces the necessity of performing a very careful evaluation of alloantibodies as well as the importance of evaluating all available sera.
A comment is needed about the patient who experienced graft loss due to early humoral rejection: in this case, antibodies were not detected prior to transplantation nor in sera taken during the first 2 weeks post-transplant when a donor-specific antibody against A68 was identified. We cannot exclude the possibility that this antibody was already present before transplant and that its titre increased after new interaction with the antigen. Again, in this case only cytotoxicity cross-match, and not flow-cytometry cross-match, had been performed and found negative.
It should be mentioned that avoiding antigens against which antibodies have been detected increased the HLA matching. In fact, average mismatch was 2.3 versus 3.7 for standard patients.
Obviously, searching for 'perfect' organs increases the patient's time on the waiting list, but the access to a much larger pool of donors minimizes this aspect. In fact, children had access to all donors in Italy (in the last 5 years, the average total number of donors in our country was 1135) and not only paediatric donors. Of course, this could reduce the quality of the organs, and thus physicians often exclude the oldest donors, even though there is no specific policy in this regard. A child with specific clinical problems might receive an organ from an older donor, depending on the physician's judgment.
This programme does not exclude the careful screening of living donors. During the same period, three additional patients were transplanted with kidneys from living donors. Donors were selected using exactly the same method as used for other patients following a careful screening of circulating antibodies and selecting donors with no prohibited antigens. All three children are in good health condition and no rejection has occurred in any of them after a follow-up of 3-4 years.
In any case, average waiting time increased from 18 to 30 months, which is acceptable considering the benefits associated with the absence of immunologic memory against the graft and the possible better long-term outcome, which should be similar to the results of standard patients. Yet the net balance of the list demonstrates an increase in the total number of sensitized patients waiting for an organ. To be able to further improve this approach, which in our opinion is very successful, it would be necessary to expand the donor pool. This could only be achieved by increasing the number of centres participating in the programme, possibly including all European countries and using a computerized guided exchange programme.
Even considering the short follow-up, current graft survival is good. Ideally, these patients should have an outcome comparable to that expected in standard patients. Standard immunosuppression may be used and no particular adverse events are expected to occur following desensitization procedures.
We are aware that our system is not 'perfect' and that there is still room for improvement. At least two humoral rejections could probably have been prevented by implementing flowcytometry cross-match for all patients.
In any event, we believe that it should also be possible to find a compatible kidney for highly sensitized patients. Since children have a long life expectancy and the long-term results of desensitization programmes are not (yet) convincing, we suggest that these programmes should be reserved for selected cases where compatible organs cannot be found within a reasonable time span.
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